Morgan Stanley Sticks to Their Buy Rating for Healthpeak Properties (DOC)

In a report released today, Ronald Kamdem from Morgan Stanley maintained a Buy rating on Healthpeak Properties, with a price target of $20.00.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

According to TipRanks, Kamdem is a 5-star analyst with an average return of 9.3% and a 62.60% success rate. Kamdem covers the Real Estate sector, focusing on stocks such as Realty Income, Healthpeak Properties, and American Healthcare REIT, Inc..

In addition to Morgan Stanley, Healthpeak Properties also received a Buy from Mizuho Securities’s Vikram Malhotra in a report issued on May 18. However, on May 13, UBS assigned a Hold rating to Healthpeak Properties (NYSE: DOC).

Based on Healthpeak Properties’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $752.95 million and a net profit of $193.63 million. In comparison, last year the company earned a revenue of $702.89 million and had a net profit of $42.83 million

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DOC in relation to earlier this year. Earlier this month, Scott R Bohn, the CDO and Head of Lab of DOC sold 10,989.00 shares for a total of $213,736.05.